
Proteases are naturally occurring protein-cleaving enzymes that regulate a wide variety of biological processes. Catalyst Biosciences is harnessing the power of these enzymes as bio-pharmaceuticals by either redirecting them to cleave specific proteins that promote disease or improving existing marketed protease-based drugs. Catalyst calls these engineered proteases "Alterase™ Therapeutics." Our technology consists of methods to identify proteases with tailor-made specificity or improved pharmacological properties. Catalyst’s Alterases represent an exciting new modality in protein therapeutics. Alterases have the potential to be very powerful therapeutics due to their catalytic nature. Unlike standard small molecule or antibody drugs, a single protease molecule can inactivate hundreds to thousands of target molecules, resulting in higher efficacy and lowered dosing.
![]()
July 7 , 2009 - CATALYST BIOSCIENCES ANNOUNCES AGREEMENT WITH MEDIMMUNE TO DISCOVER AND DEVELOP ENGINEERED PROTEASE THERAPEUTICS
June 30 , 2009 - CATALYST BIOSCIENCES AND WYETH PHARMACEUTICALS ANNOUNCE WORLDWIDE COLLABORATION
March 24, 2009 - CATALYST BIOSCIENCES EXPANDS SCIENTIFIC ADVISORY BOARD
December 3, 2008 - CATALYST BIOSCIENCES RAISES $40 MILLION IN SERIES C FINANCING
May 6, 2008 - CATALYST BIOSCIENCES SELECTS DRUG DEVELOPMENT CANDIDATE IN FACTOR VIIA PROGRAM FOR HEMOPHILIA




